Cytokine modulators as novel therapies for asthma

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 81-98

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Inteleukin 10; Inteleukin 12; Interleukin 4; Interleukin 5

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTIASTHMATIC AGENT; BAY 36 1677; CHEMOKINE INHIBITOR; CHEMOKINE RECEPTOR CCR2 INHIBITOR; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CHEMOKINE RECEPTOR CCR4 INHIBITOR; CORTICOSTEROID; CYTOKINE; CYTOKINE INHIBITOR; I KAPPA B; IMMUNOMODULATING AGENT; INTERFERON; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 4 ANTIBODY; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9 ANTIBODY; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY DETECTION; ANTIINFLAMMATORY ACTIVITY; ASTHMA; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SPECIFICITY; DRUG SYNTHESIS; EOSINOPHILIA; HUMAN; INFLAMMATION; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; REVIEW; RISK ASSESSMENT; SIDE EFFECT;

ASTHMA; CHEMOKINES; CYTOKINES; HUMANS; INTERFERONS; INTERLEUKIN-12; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKIN-9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036168725     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.111901.111143     Document Type: Review

References (84)

1. Inflammatory mediators of asthma: An update
2. Cytokines in asthma
3. New treatments for asthma
4. Therapeutic strategies for allergic diseases
5. New directions in allergic disease: Mechanism-based anti-inflammatory therapies
6. Inhibitory cytokines in asthma
7. Endogenous inhibitory mechanisms in asthma
8. The role of interleukin-5 in allergic eosinophilic disease
9. Inhibitory effect of the TRFK-5 anti IL-5 antibody in a guinea pig model of asthma
10. Effects of an antibody to interleukin-5 in a monkey model of asthma
11. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response
12. Results of a phase I trial with SCH55700, a humanized anti-IL-5 antibody in severe persistent asthma
13. A novel T cell-regulated mechanism modulating allergen-induced airways hyperre-activity in BALB/c mice independently of IL-4 and IL-5
14. Airway subepithelial fibrosis in a murine model of atopic asthma: Suppression by dexamethasone or anti-interleukin-5 antibody
15. Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma
16. Interleukin-4: Its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists
17. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice
18. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial
19. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma
20. An immune cell-selective interleukin 4 agonist
21. IL-4/IL-13 signaling beyond JAK/STAT
22. STAT6: An intracellular target for the inhibition of allergic disease
23. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction
24. Interleukin-13: Central mediator of allergic asthma
25. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells
26. Interleukin-4 and interleukin-13: Their similarities and discrepancies
27. IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders
28. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells
29. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma
30. Interleukin-9 receptor expression in asthmatic airways in vivo
31. Interleukin-9 as a therapeutic target for asthma
32. Expression of interleukin-1 beta (IL-β) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium
33. Interleukin-1 receptor antagonist: Role in biology
34. Biologic activities of IL-1 and its role in human disease
35. The potential role of tumor necrosis factor α in asthma
36. Infliximab: A review of its use in the management of rheumatoid arthritis
37. Etanercept: A review of its use in rheumatoid arthritis
38. New alpha-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors
39. IL-10: A potential therapy for allergic inflammation?
40. Interleukin-10 regulation in normal subjects and patients with asthma
41. Inhaled corticosteroids increase IL-10 but reduce MIP-1α, GM-CSF and IFN-γ release from alveolar macrophages in asthma
42. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice
43. Role of interleukin 10 in specific immunotherapy
44. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease
45. Interleukin-10 does not mediate the inhibitory effect of PDE4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumor necrosis factor-α generation from human peripheral blood monocytes
46. Nebulized IFN-γ inhibits the development of secondary allergic responses in mice
47. The effects of nebulized recombinant interferon-γ in asthmatic airways
48. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy
49. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ
50. Treatment with IFN-α in corticosteroid-unresponsive asthma
51. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
52. Interleukin-12 inhibits antigen-induced airway hyperresponsiveness, inflammation and Th2 cytokine expression in mice
53. Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma
54. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
55. Effects of recombinant human interleukin-12 on eosinophils, airway hyperreactivity and the late asthmatic response
56. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production
57. Interleukin-18, a proinflammatory cytokine
58. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels
59. The biology of chemokines and their receptors
60. The strategy of blocking the chemokine system to combat disease
61. Non-redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung
62. Eotaxin: From an eosinophilic chemokine to a major regulator of allergic reactions
63. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors
64. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells
65. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (intrinsic) asthmatics
66. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
67. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration
68. Expression of RANTES mRNA and protein in airways of patients with mild asthma
69. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3
70. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/-mice: The role of mast cells
71. Release of RANTES, MIP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge
72. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo
73. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits IL-1β-induced histone H4 acetylation on lysines 8 and 12
74. Transcription factors of the NFAT family: Regulation and function
75. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma
76. Effect of suplatast tosilate (IPD- 1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines
77. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: A double-blind randomised study
78. Phosphodiesterase isoenzymes
79. Nuclear factor-κB: A pivotal transcription factor in chronic inflammatory diseases
80. Kinase regulation in inflammatory response
81. Differential IKK activation and IκBα degradation by interleukin-1β and tumor necrosis factor-α in human U937 monocytic cells: Evidence for additional regulatory steps in κB-dependent transcription
82. Both erk and p38 kinases are necessary for cytokine gene transcription
83. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-αB-independent mechanism
84. Inhibition of p38 MAP kinase as a therapeutic strategy